Growth Metrics

Gilead Sciences (GILD) Total Non-Current Liabilities (2016 - 2026)

Gilead Sciences filings provide 17 years of Total Non-Current Liabilities readings, the most recent being $35.2 billion for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 8.38% to $35.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $35.2 billion, a 8.38% decrease, with the full-year FY2025 number at $35.2 billion, down 8.38% from a year prior.
  • Total Non-Current Liabilities hit $35.2 billion in Q4 2025 for Gilead Sciences, down from $36.2 billion in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $48.2 billion in Q1 2021 to a low of $34.6 billion in Q2 2024.
  • Median Total Non-Current Liabilities over the past 5 years was $38.1 billion (2022), compared with a mean of $38.8 billion.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 50.74% in 2021 and later fell 16.0% in 2022.
  • Gilead Sciences' Total Non-Current Liabilities stood at $42.1 billion in 2021, then fell by 9.67% to $38.0 billion in 2022, then increased by 0.13% to $38.1 billion in 2023, then grew by 0.72% to $38.4 billion in 2024, then fell by 8.38% to $35.2 billion in 2025.
  • The last three reported values for Total Non-Current Liabilities were $35.2 billion (Q4 2025), $36.2 billion (Q3 2025), and $35.3 billion (Q2 2025) per Business Quant data.